Medicrea International

Medicrea International SA is a France-based company that specializes in the design and manufacture of medical devices. The Company's product range includes polyaxial implants, impacted lumbar cage, polyaxial spine system, cervical compressive staples, cervical IBD, Lumbar IBD, cervical cage and bone substitutes. The Company has manufacturing facilities in La Rochelle, France. It is operational through such subsidiaries as Medicrea UK, based in the United Kingdom, Medicrea USA, based in the United States and Medicrea Technologies, based in France.
  • TickerALMED
  • ISINFR0004178572
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

A director bought 60,000 shares at 3.197EUR and

A director at Medicrea International bought 60,000 shares at 3.197EUR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 17/05/2018

Toutes les autorisations d'agir sur le capital proposées lors de la présente assemblée sont utilisables en période d'offre publique, ce qui en fait un arsenal anti-OPA non favorable aux intérêts des actionnaires. Par ailleurs, la société propose la nomination de Pierre Olivier, le Directeur Général de sa filiale américaine. Or, le conseil est déjà composé en intégralité d'administrateurs sujets à conflits d'intérêts ; il serait préférable que la société propose la nomination d'administrateur compétents réellement indépendants.

Anaïs Dudout

Etude de l'AG du 08/11/2017

La société soumet à l'approbation des actionnaires trois autorisations : une opération d'émission d'options de souscription ou d'achat (résolution 1), une attribution d'actions gratuites (résolution 2) et une émission réservée aux salariés (résolution 3). La société a désiré augmenter le plafond de l'ensemble des autorisations de 7,5% du "Plafond Global I" défini par l'assemblée générale du 11 mai 2017. Elle justifie ces opérations par le besoin de "continuer à disposer de ce système [de rémunération] pour associer le personnel, notamment la filiale aux Etats-Unis, et les dirigeants de la soc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch